Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of [177Lu]Lu-TEFAPI-06 in Metastatic Solid Tumors
NCT07299253Phase 1Completed
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [177Lu]Lu-TEFAPI-06 in metastatic solid tumors, sponsored by Second Hospital of Lanzhou University. Primary endpoint: Incidence and Severity of Treatment-Emergent Adverse Events at 30 days. Started Aug 2023; status: completed.
02
Drugs
[177Lu]Lu-TEFAPI-06
03
Conditions
metastatic solid tumors
Beyond the preview
Go deeper on NCT07299253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07299253.